

IFN-alpha 1/IFNA13 Protein, Human (HEK293, His)

Cat. No.:	HY-P70241
Synonyms:	rHuInterferon alpha-1, His; Interferon alpha-1/13; IFN-alpha-1/13; Interferon alpha-D; LeIF D; IFNA1; IFNA13
Species:	Human
Source:	HEK293
Accession:	P01562 (C24-E189)
Gene ID:	3439/3447
Molecular Weight:	Approximately 19-20 kDa

PROPERTIES

AA Sequence	<p> C D L P E T H S L D N R R T L M L L A Q M S R I S P S S C L M D R H D F G F P Q E E F D G N Q F Q K A P A I S V L H E L I Q Q I F N L F T T K D S S A A W D E D L L D K F C T E L Y Q Q L N D L E A C V M Q E E R V G E T P L M N A D S I L A V K K Y F R R I T L Y L T E K K Y S P C A W E V V R A E I M R S L S L S T N L Q E R L R R K E </p>
Biological Activity	<p>1. Measured by its ability to inhibit the proliferation of TF-1 human erythroleukemic cells. The ED₅₀ this effect is 0.327 ng/mL, corresponding to a specific activity is 3.058×10⁶ units/mg.</p> <p>2. Human IFN-alpha 1 immobilized on CM5 Chip can bind IFNAR2 with an affinity constant of 19.04 nM as determined in a SPR assay.</p>
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4 or PBS, pH 7.4.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	IFN-alpha 1 (IFNA1; IFN-α1), belongs to the alpha/beta interferon family, is produced by macrophages with antiviral activities ^[1] . Interferon (IFN) is originally identified as a substance 'interfering' with viral replication in vitro. IFN-α/β and
-------------------	---

related molecules are classified as type I IFNs, as for the other two types of type II IFN (IFN- γ) and type III IFNs (IFN- λ), respectively^[2].

IFNs binds to one of three type-specific receptors, which leads to the activation of JAK1 and TYK2^[3]. This signal transduction results in phosphorylation of STAT1 and STAT2 and eventually in an association with IFN regulatory factor 9 (IRF9) and formation of the IFN-stimulated gene factor 3 (ISGF3) complex. Thus the ISGF3 complex induces transcription of IFN-stimulated genes (ISGs), with subsequent immunomodulatory effects on both innate and adaptive immune responses^[4].

The interactions of type I IFN with the immune system is important for the generation of a durable antitumor response through its effects on dendritic cells (DC)^[5]. IFN has been widely used for animal disease model, and the sequence of amino acids in IFNA1 protein of human is very different from mouse (62.96%).

REFERENCES

- [1]. Zoon KC, et al. Purification and characterization of multiple components of human lymphoblastoid interferon-alpha. *J Biol Chem.* 1992 Jul 25;267(21):15210-6.
- [2]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. *Immunol Rev.* 2008 Dec;226:29-40.
- [3]. Gibbert K, et al. IFN- α subtypes: distinct biological activities in anti-viral therapy. *Br J Pharmacol.* 2013 Mar;168(5):1048-58.
- [4]. De Ceuninck F, et al. IFN- α : A key therapeutic target for multiple autoimmune rheumatic diseases. *Drug Discov Today.* 2021 Oct;26(10):2465-2473.
- [5]. Lapenta C, et al. IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. *Vaccines (Basel).* 2020 Oct 19;8(4):617.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA